Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Genetown symbols : TAK save search
FDA Approves Takeda’s EOHILIA (budesonide oral suspension), the First and Only Oral Treatment in the U.S. for Eosinophilic Esophagitis (EoE)
Published: 2024-02-12 (Crawled : 14:00) - biospace.com/
TAK | News | $13.23 -1.12% 0.0% 920K
|
Health Technology
|
| O: 0.07%
H: 0.46%
C: 0.42%
fda first treatment
Takeda Named Global Top Employer for Seventh Consecutive Year
Published: 2024-01-18 (Crawled : 13:00) - biospace.com/
TAK | News | $13.23 -1.12% 0.0% 920K
|
Health Technology
|
| O: -0.13%
H: 0.27%
C: 0.2%
year global
Takeda Announces China NMPA Approval of LIVTENCITY® (maribavir) for the Treatment of Adults With Post-transplant Cytomegalovirus (CMV) Refractory to Prior Therapies
Published: 2023-12-21 (Crawled : 00:00) - biospace.com/
TAK | News | $13.23 -1.12% 0.0% 920K
|
Health Technology
|
| O: 2.05%
H: 0.29%
C: 0.0%
livtencity approval cytomegalovirus treatment china
European Commission Approves ADCETRIS® (brentuximab vedotin) for the Treatment of Adult Patients with Previously Untreated CD30+ Stage III Hodgkin Lymphoma in Combination with AVD
Published: 2023-10-18 (Crawled : 22:00) - biospace.com/
TAK | News | $13.23 -1.12% 0.0% 920K
|
Health Technology
|
| O: -1.61%
H: 0.14%
C: -0.27%
cd30 adcetris treatment
Takeda Announces Approval of CUVITRU™ Subcutaneous Immunoglobulin in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia
Published: 2023-09-25 (Crawled : 15:00) - biospace.com/
TAK | News | $13.23 -1.12% 0.0% 920K
|
Health Technology
|
| O: 0.57%
H: 0.38%
C: 0.25%
japan approval
Takeda Announces FDA Acceptance of BLA Resubmission for Investigational Subcutaneous Administration of Entyvio® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Ulcerative Colitis
Published: 2023-04-27 (Crawled : 13:00) - biospace.com/
TAK | News | $13.23 -1.12% 0.0% 920K
|
Health Technology
|
| O: 0.0%
H: 0.36%
C: 0.3%
entyvio fda active resubmission therapy
Takeda To Acquire Exclusive Worldwide (ex-China) License of HUTCHMED’s Fruquintinib, a Highly Selective, Oral VEGFR1/2/3 Tyrosine Kinase Inhibitor
Published: 2023-01-23 (Crawled : 10:00) - biospace.com/
TAK | News | $13.23 -1.12% 0.0% 920K
|
Health Technology
|
| O: -0.25%
H: 0.4%
C: -0.25%
acquire license
LogicBio Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Updates
Published: 2022-11-14 (Crawled : 15:00) - biospace.com/
TAK | News | $13.23 -1.12% 0.0% 920K
|
Health Technology
|
| O: -1.95%
H: 1.58%
C: 0.96%
LOGC | $2.07 -0.48%
|
Health Technology
|
| O: 0.49%
H: 0.0%
C: 0.0%
logicbio therapeutics financial results
Takeda Receives Positive CHMP Opinion Recommending Approval of Dengue Vaccine Candidate in EU and Dengue-Endemic Countries
Published: 2022-10-14 (Crawled : 15:00) - biospace.com/
TAK | News | $13.23 -1.12% 0.0% 920K
|
Health Technology
|
| O: 0.62%
H: 0.69%
C: -0.69%
candidate chmp vaccine dengue approval positive tak-003 qdengue
Takeda’s QDENGA®▼ (Dengue Tetravalent Vaccine [Live, Attenuated]) Approved in Indonesia for Use Regardless of Prior Dengue Exposure
Published: 2022-08-22 (Crawled : 17:00) - biospace.com/
TAK | News | $13.23 -1.12% 0.0% 920K
|
Health Technology
|
| O: -1.01%
H: 1.16%
C: 0.44%
qdenga vaccine approved qdengue
Takeda’s Dengue Vaccine Candidate Provides Continued Protection Against Dengue Fever Through 4.5 Years in Pivotal Clinical Trial
Published: 2022-06-09 (Crawled : 09:00) - biospace.com/
TAK | News | $13.23 -1.12% 0.0% 920K
|
Health Technology
|
| O: 0.18%
H: 0.66%
C: -0.88%
vaccine trial qdengue
Takeda and Seagen to Highlight ADCETRIS® Combination Data Showing Statistically Significant Improvement in Overall Survival (OS) for Patients with Advanced Hodgkin Lymphoma
Published: 2022-05-26 (Crawled : 23:00) - biospace.com/
TAK | News | $13.23 -1.12% 0.0% 920K
|
Health Technology
|
| O: -0.17%
H: 0.0%
C: 0.0%
SGEN | $228.74 0.1% 20M
|
Health Technology
|
| O: 0.64%
H: 1.53%
C: 0.82%
adcetris
Oak Hill Bio Sponsors Industry Symposium at International Conference on Clinical Neonatology
Published: 2022-05-25 (Crawled : 13:00) - biospace.com/
TAK | News | $13.23 -1.12% 0.0% 920K
|
Health Technology
|
| O: -0.7%
H: 0.0%
C: 0.0%
conference symposium international
LogicBio Therapeutics Reports First Quarter 2022 Financial Results and Highlights Recent Business Updates
Published: 2022-05-16 (Crawled : 13:00) - biospace.com/
TAK | News | $13.23 -1.12% 0.0% 920K
|
Health Technology
|
| O: -0.14%
H: 0.0%
C: 0.0%
LOGC | $2.07 -0.48%
|
Health Technology
|
| O: 10.3%
H: 5.66%
C: -2.27%
therapeutics results
Takeda Announces Approval of Nuvaxovid® COVID-19 Vaccine for Primary and Booster Immunization in Japan
Published: 2022-04-19 (Crawled : 06:00) - biospace.com/
TAK | News | $13.23 -1.12% 0.0% 920K
|
Health Technology
|
| O: -2.23%
H: 0.0%
C: 0.0%
covid-19 nuvaxovid vaccine approval
Takeda’s TAKHZYRO® (lanadelumab-flyo) Prefilled Syringe Now Available for People With Hereditary Angioedema (HAE) Ages 12 Years and Older in the United States
Published: 2022-04-18 (Crawled : 13:00) - biospace.com/
TAK | News | $13.23 -1.12% 0.0% 920K
|
Health Technology
|
| O: -1.56%
H: 0.0%
C: 0.0%
takhzyro order hereditary angioedema
Oak Hill Bio Announces Formation of Board of Directors
Published: 2022-04-12 (Crawled : 13:00) - biospace.com/
TAK | News | $13.23 -1.12% 0.0% 920K
|
Health Technology
|
| O: 0.07%
H: 0.47%
C: -0.4%
NVO | News | $126.16 -1.93% -0.23% 3.1M
|
Health Technology
|
| O: -3.41%
H: 1.22%
C: 0.49%
GSK | News | $40.86 -0.92% -0.15% 1.7M
|
Health Technology
|
| O: -0.36%
H: 0.0%
C: 0.0%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -3.25%
H: 0.0%
C: 0.0%
Alofisel®▼ (darvadstrocel) Shows Clinical Remission Rate at Six-Months in the Real-World INSPIRE Study Interim Analysis Consistent with the Pivotal Clinical ADMIRE-CD Study1,2
Published: 2022-02-18 (Crawled : 12:30) - biospace.com/
TAK | News | $13.23 -1.12% 0.0% 920K
|
Health Technology
|
| O: 0.13%
H: 0.52%
C: 0.46%
alofisel cel
Oak Hill Bio Launches With Pipeline and Senior Leadership From Takeda
Published: 2022-02-01 (Crawled : 12:30) - biospace.com/
TAK | News | $13.23 -1.12% 0.0% 920K
|
Health Technology
|
| O: 0.07%
H: 1.53%
C: 1.32%
GSK | News | $40.86 -0.92% -0.15% 1.7M
|
Health Technology
|
| O: 0.45%
H: 0.53%
C: 0.42%
FDA Approves Prophylactic Treatment with VONVENDI® [von Willebrand Factor (Recombinant)] for Adult Patients Living with Severe Type 3 von Willebrand Disease (VWD)
Published: 2022-01-31 (Crawled : 15:00) - biospace.com/
TAK | News | $13.23 -1.12% 0.0% 920K
|
Health Technology
|
| O: -0.14%
H: 0.0%
C: 0.0%
vonvendi treatment fda disease
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.